Achieve Life Sciences, Inc.

ACHV · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.9%

Institutions82.0%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	–	–	–	–	–	–	–	$18.20M	$27.10M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$54.65M	-$39.83M	-$33.15M	-$4.72M	-$16.39M	-$12.69M	-$10.58M	-$20.13M	-$16.80M	-$26.24M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.25	$-1.24	$-4.08	$-1.11	$-1.00	$-3.00	$-2.00	$0.00	$0.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.25	$-1.24	–	–	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$20.93M	$12.75M	$43.00M	$35.85M	$16.66M	$9.52M	$5.28M	$15.23M	$34.31M	$27.90M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$41.79M	$38.63M	$47.52M	–	$21.08M	$19.08M	$9.89M	$27.47M	$58.21M	$56.29M
All of the company's interest-bearing borrowings, short and long term combined.	$3.70M	–	–	–	–	–	–	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$20.27M	$17.73M	$19.47M	–	$3.03M	$3.28M	$2.01M	$8.50M	$20.77M	$22.23M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$21.52M	$20.90M	$28.04M	–	$18.05M	$15.80M	$7.88M	$18.97M	-$176.81M	-$159.96M

Cash Flow Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$49.50M	-$29.80M	-$29.40M	–	-$15.22M	-$10.62M	-$9.11M	-$29.68M	-$9.10M	-$17.31M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$3000	–	–	–	$53000	$46000	–	$46000	$371000	$82000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$49.50M	–	–	–	-$15.27M	-$10.67M	–	-$29.73M	-$9.47M	-$17.39M

	You	Peer avg
P/E	–	2.9
Revenue Growth	–	-22.6%
ROE	-845.0%	-4.8%

Achieve Life Sciences, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison